[go: up one dir, main page]

SK403591A3 - 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents - Google Patents

2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents Download PDF

Info

Publication number
SK403591A3
SK403591A3 SK4035-91A SK403591A SK403591A3 SK 403591 A3 SK403591 A3 SK 403591A3 SK 403591 A SK403591 A SK 403591A SK 403591 A3 SK403591 A3 SK 403591A3
Authority
SK
Slovakia
Prior art keywords
ranitidine hydrochloride
ranitidine
pharmaceutical product
excipient
2vwd
Prior art date
Application number
SK4035-91A
Other languages
English (en)
Slovak (sk)
Other versions
SK277922B6 (en
Inventor
Derek L Crookes
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10516407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK403591(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of SK277922B6 publication Critical patent/SK277922B6/sk
Publication of SK403591A3 publication Critical patent/SK403591A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
SK4035-91A 1980-10-01 1991-12-23 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents SK403591A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB8031634 1980-10-01

Publications (2)

Publication Number Publication Date
SK277922B6 SK277922B6 (en) 1995-08-09
SK403591A3 true SK403591A3 (en) 1995-08-09

Family

ID=10516407

Family Applications (1)

Application Number Title Priority Date Filing Date
SK4035-91A SK403591A3 (en) 1980-10-01 1991-12-23 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents

Country Status (29)

Country Link
US (2) US4521431A (it)
JP (1) JPS5791983A (it)
KR (1) KR870001431B1 (it)
AT (1) AT389696B (it)
AU (1) AU549119B2 (it)
BE (1) BE890574A (it)
CA (1) CA1202638A (it)
CH (1) CH652122A5 (it)
CZ (1) CZ280885B6 (it)
DE (1) DE3139134A1 (it)
DK (2) DK167794B1 (it)
ES (1) ES8301954A1 (it)
FR (1) FR2491067A1 (it)
GR (1) GR72499B (it)
HK (1) HK97985A (it)
IE (1) IE51604B1 (it)
IL (1) IL63968A (it)
IT (1) IT1143237B (it)
KE (1) KE3549A (it)
LU (1) LU83661A1 (it)
MY (1) MY8500747A (it)
NL (1) NL8104482A (it)
NZ (1) NZ198522A (it)
PH (2) PH19489A (it)
PT (1) PT73744B (it)
SE (1) SE453500B (it)
SK (1) SK403591A3 (it)
ZA (1) ZA816809B (it)
ZW (1) ZW24481A1 (it)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR242029A1 (es) * 1983-07-15 1993-02-26 Richter Gedeon Vegyeszet Procedimiento para la preparacion del clorhidrato de 1-(2-(5- dimetilaminometil-2-(furilmetiltio)-etil))-amino-1-metilamino-2-nitroetileno
GB8629781D0 (en) * 1986-12-12 1987-01-21 Glaxo Group Ltd Pharmaceutical compositions
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorbate comprising ranitidine together with a synthetic cation exchange resin, its preparation and pharmaceutical compositions containing it
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5169864A (en) * 1991-11-15 1992-12-08 Baxter International Inc. Unbuffered premixed ranitidine formulation
CN1048984C (zh) * 1991-12-20 2000-02-02 多坎化学有限公司 晶形1呋喃硝胺氢氯化物的制备
US5338871A (en) * 1991-12-20 1994-08-16 Torcan Chemical Ltd. Preparation of form 1 ranitidine hydrochloride
WO1994020505A1 (en) * 1993-03-12 1994-09-15 The Upjohn Company Crystalline ceftiofur free acid
DE4341310A1 (de) * 1993-12-03 1995-06-08 Hexal Pharma Gmbh Tablette oder Kapsel mit einem Gehalt an stabilem Ranitidinhydrochlorid Form 1
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
CA2120874E (en) * 1994-04-08 2002-01-08 Keshava Murthy Form of form 1 ranitidine
EP0754182A1 (en) * 1994-04-08 1997-01-22 Brantford Chemicals Inc. Form 1 ranitidine hydrochloride with increased density
ATE207481T1 (de) 1994-04-15 2001-11-15 Upjohn Co Kristallformen von 1-(5-methansulfonamidoindolyl- 2-carbonyl)-4-(3-(1-methylethylamino)-2- pyridinyl) piperazin
NZ272054A (en) * 1994-05-13 1996-05-28 Ranbaxy Lab Ltd Process for producing form 1 ranitidine hydrochloride
IN181698B (it) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
IN181699B (it) * 1994-05-13 1998-09-05 Ranbaxy Lab Ltd
US20030045722A1 (en) * 1994-05-18 2003-03-06 Henton Daniel R. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
EP0766668B1 (en) * 1994-05-18 2002-07-17 Aventis Pharmaceuticals Inc. Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudormophs thereof
EP0694540B1 (en) 1994-06-24 1998-08-19 Ranbaxy Laboratories Limited Process for the manufacture of form 1 ranitidine hydrochloride
CA2201735A1 (en) * 1994-11-18 1996-05-30 The Upjohn Company A new physically stable solid form of a fluoroquinolone
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
US5663381A (en) * 1995-04-21 1997-09-02 Hexal Pharmaceuticals, Inc. Process for preparing form 1 ranitidine hydrochloride
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
WO1997035853A1 (en) * 1996-03-25 1997-10-02 Hoechst Marion Roussel, Inc. Process for the preparation of form 1 ranitidine hydrochloride
DK0987256T3 (da) 1997-08-08 2002-02-11 Aventis Pharma Gmbh Krystalform af N-(4-trifluormethylphenyl)-5-methylisoxazol-4-carboxylsyreamid
US6287693B1 (en) * 1998-02-25 2001-09-11 John Claude Savoir Stable shaped particles of crystalline organic compounds
IT1317858B1 (it) * 2000-02-29 2003-07-15 Pharmexcel S R L Allomorfo del cloridrato dell'isomero z di derivato dialchilamminofurano, procedimento per la sua produzione e composizione
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US20020183553A1 (en) * 2000-10-19 2002-12-05 Ben-Zion Dolitzky Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
US20060173064A1 (en) * 2001-08-24 2006-08-03 Lippa Arnold S (-)-1-(3,4-Dichlorophenyl)-3-azabi cyclo[3.1.0]hexane, compositions thereof, and uses for treating alcohol-related disorders
US6569887B2 (en) * 2001-08-24 2003-05-27 Dov Pharmaceuticals Inc. (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake
US7235655B2 (en) * 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
TW200409746A (en) * 2002-07-26 2004-06-16 Theravance Inc Crystalline β2 adrenergic receptor agonist
US20080081834A1 (en) 2002-07-31 2008-04-03 Lippa Arnold S Methods and compositions employing bicifadine for treating disability or functional impairment associated with acute pain, chronic pain, or neuropathic disorders
US7166641B2 (en) * 2002-10-02 2007-01-23 Yung Shin Pharmaceutical Industrial Co., Ltd. Pharmaceutically acceptable salts containing local anesthetic and anti-inflammatory activities and methods for preparing the same
JP2006519162A (ja) * 2002-11-08 2006-08-24 ディオーブイ ファーマシューティカル，インク． ビシファジン塩酸塩の多形
TW200510277A (en) * 2003-05-27 2005-03-16 Theravance Inc Crystalline form of β2-adrenergic receptor agonist
US7384557B2 (en) * 2003-07-14 2008-06-10 Applied Ambient Extraction Process Consultants, Llc Method and apparatus for removing solute from a solid solute-bearing product
TWI328006B (en) 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US20070043100A1 (en) 2005-08-16 2007-02-22 Hagen Eric J Novel polymorphs of azabicyclohexane
US20060100263A1 (en) * 2004-11-05 2006-05-11 Anthony Basile Antipyretic compositions and methods
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
CA2659215C (en) * 2005-07-27 2018-07-10 Dov Pharmaceutical, Inc. Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US20080045725A1 (en) * 2006-04-28 2008-02-21 Murry Jerry A Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane
CN101534642A (zh) * 2006-10-20 2009-09-16 神隆药业新加坡私人有限公司 用于制备结晶无水多西紫杉醇的方法
US8138377B2 (en) 2006-11-07 2012-03-20 Dov Pharmaceutical, Inc. Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
TW201011043A (en) * 2008-06-20 2010-03-16 Chugai Pharmaceutical Co Ltd Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives
CA2837453C (en) 2011-06-30 2017-04-11 Toray Industries, Inc. Crystals of glycine derivative and pharmaceutical use thereof
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
CN106397374A (zh) * 2015-05-26 2017-02-15 烟台市华文欣欣医药科技有限公司 一种制备治疗胃病的药物盐酸雷尼替丁化合物的方法
CN105030694A (zh) * 2015-08-04 2015-11-11 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃溃疡的药物盐酸雷尼替丁组合物干混悬剂
CN104971053A (zh) * 2015-08-05 2015-10-14 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化系统疾病的药物盐酸雷尼替丁组合物片剂
CN105055331A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物盐酸雷尼替丁组合物颗粒剂
WO2021079183A1 (en) * 2019-10-21 2021-04-29 Sms Pharmaceuticals Limited Isopropyl alcohol solvent free crystalline ranitidine hydrochloride form-2 which is free of nitrosamine (ndma) impurity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1565966A (en) * 1976-08-04 1980-04-23 Allen & Hanburys Ltd Aminoalkyl furan derivatives
US4233302A (en) * 1977-12-23 1980-11-11 Glaxo Group Limited Amine derivatives and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
KR870001431B1 (ko) 1987-08-06
HK97985A (en) 1985-12-13
AU7595581A (en) 1982-04-08
PH21761A (en) 1988-02-18
SK277922B6 (en) 1995-08-09
SE8105812L (sv) 1982-04-02
DK167923B1 (da) 1994-01-03
CZ403591A3 (en) 1994-01-19
CA1202638A (en) 1986-04-01
ZA816809B (en) 1983-05-25
SE453500B (sv) 1988-02-08
PT73744B (en) 1983-10-31
LU83661A1 (fr) 1983-06-08
BE890574A (fr) 1982-04-01
MY8500747A (en) 1985-12-31
PT73744A (en) 1981-10-01
DE3139134C2 (it) 1990-04-19
ES505951A0 (es) 1983-01-01
CZ280885B6 (cs) 1996-04-17
DK33792D0 (da) 1992-03-12
FR2491067B1 (it) 1984-09-07
ZW24481A1 (en) 1983-04-27
AU549119B2 (en) 1986-01-16
US4521431A (en) 1985-06-04
JPH0443070B2 (it) 1992-07-15
DK436281A (da) 1982-04-02
CH652122A5 (fr) 1985-10-31
DK167794B1 (da) 1993-12-13
PH19489A (en) 1986-05-14
GR72499B (it) 1983-11-15
IT8149407A0 (it) 1981-10-01
IT1143237B (it) 1986-10-22
JPS5791983A (en) 1982-06-08
FR2491067A1 (fr) 1982-04-02
IE51604B1 (en) 1987-01-21
KE3549A (en) 1985-08-16
US4672133A (en) 1987-06-09
NZ198522A (en) 1985-07-12
AT389696B (de) 1990-01-10
IE812287L (en) 1982-04-01
KR830007070A (ko) 1983-10-14
IL63968A (en) 1985-10-31
NL8104482A (nl) 1982-05-03
DK33792A (da) 1992-03-12
DE3139134A1 (de) 1982-05-19
ATA422281A (de) 1989-06-15
IL63968A0 (en) 1981-12-31
ES8301954A1 (es) 1983-01-01

Similar Documents

Publication Publication Date Title
SK403591A3 (en) 2-ranitidine hydrochloride form, method of its preparation and pharmaceutical product with its contents
US5914425A (en) Modifications of 2-amino-4-(4-5fluorobenzylamino)-1-ethoxycarbonylaminobenzene, and processes for their preparation
AU2017238917B2 (en) Novel acid addition salt of 1-(5-(2,4-difluorophenyl)-1-((3- fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrol-3-yl)-N- methylmethanamine
GB2084580A (en) Aminoalkyl Furan Derivative
CN102321019B (zh) 喹啉化合物的晶形及其生产方法
SK286422B6 (sk) Hydrát 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-dión maleínanu, spôsob jehovýroby, farmaceutický prípravok s jeho obsahom a jeho použitie
IL101358A (en) Crystalline tiagabine hydrochloride monohydrate its preparation and pharmaceutical composition containing it
JPS60215689A (ja) 結晶性セフタジダイム塩
HU195486B (en) Process for preparing new pyridine derivatives
US6703410B1 (en) Crystal forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
JP4000397B2 (ja) モルヒネ−６−グルクロニドの新しい結晶形熊
US5663381A (en) Process for preparing form 1 ranitidine hydrochloride
AU2019365166A1 (en) Crystal form of maleate of tyrosine kinase inhibitor and preparation method therefor
US3960882A (en) Chemical compounds for trichomoniasis and candidiosis treatment
IE43311B1 (en) 1-methyl-2-(pyridyloxmyethyl)-5-nitroimidazoles and process for preparing them
KR0152469B1 (ko) 아민염산염을 이용한 라니티딘 염산염의 제조방법
MXPA97008122A (en) A process for preparing ranitidine hydrochloride form
KR900005013B1 (ko) N-(2,6-이치환 방향족)-n'-피리디닐 요소 및 그 제법
MXPA01004794A (en) Crystalline forms of 3-(2, 4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide
JPH0798824B2 (ja) 免疫調節剤